

Bronchoscopically-visible massive central airway cancer cavitation is associated with metastatic disease, lack of actionable mutations and poor prognosis: a case series

Daniele Magnini,¹ Emilio Bria,^{2,3} Alessandra Cancellieri,⁴ Vanina Livi,¹ Fausto Leoncini,¹ Marco Ferrari,⁵ Teresa Bruni,⁶ Daniela Paioli,¹ Rocco Trisolini^{1,3}

¹Interventional Pulmonology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; ²Medical Oncology Division, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; ³Catholic University of the Sacred Heart, Rome; ⁴Pathology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; ⁵Interventional Pulmonology Unit, IRCCS Azienda Ospedaliero-Universitaria, Bologna; ⁶Pulmonology Division, ASST Crema – Ospedale Maggiore, Crema, Italy

Correspondence: Rocco Trisolini, Interventional Pulmonology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Largo Agostino Gemelli 8, 00168 Rome, Italy.
E-mail: rocco.trisolini@policlinicogemelli.it

Key words: bronchoscopy, cavitated tumor, hemoptysis, immunotherapy, lung cancer, radiotherapy.

Contributions: RT, EB, DM contributed to conceptualization, methodology, investigation, writing – original draft; AC, VL, FL, TB, MF, DP contributed to investigation, data curation, writing – review and editing. All of the Authors have read and approved the manuscript.

Conflict of interest: the authors declare that they have no competing interests, and all authors confirm accuracy.

Ethics approval and consent to participate: no ethical committee approval was required for this case report by the departments because this article does not contain any studies with human participants or animals.

Patient consent for publication: informed consent for publication was obtained from the patients included in this study.

Availability of data and materials: the data and materials used in the study are available upon reasonable request to the corresponding author.

Funding: none.

Received: 21 June 2023.

Accepted: 27 September 2023.

Early view: 3 October 2023.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2023

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2024; 94:2670

doi: 10.4081/monaldi.2023.2670

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Cavitating lung tumors occur in approximately 10-15% of the patients, are more commonly associated with squamous histology, and are typically located in the lung parenchyma. Herein, we describe an exceedingly rare series of five patients, four of whom treatment-naïve, whose tumor caused the disruption of the normal airway anatomy at the level of lobar or segmental bronchi, leading to the formation of an endoscopically visible cavity that ended up in the lung parenchyma or even into the pleural space. Sex (3 males, 2 females), smoking habit (2 never smokers, 2 former smokers, 1 current smoker), and histology (3 adenocarcinoma, 2 squamous cell carcinoma) were heterogeneous, but the 4 patients treatment-naïve presented with metastatic disease, poor Eastern Cooperative Oncology Group (ECOG) performance status, similar clinical complaints of long duration, and a lack of actionable mutations. The only patient who exhibited a meaningful response to treatment had the lowest symptoms' duration, the smallest size of the cavitated mass, and the best performance status at the time of diagnosis. This series provides the first comprehensive description of a rare presentation of lung cancer characterized by similar clinical complaints, delayed diagnosis, and poor prognosis.

Introduction

In the last decade, the awareness of cavitory lung tumors has increased due to the evidence of an increased risk of cavitation associated with treatment options including antiangiogenic drugs, immunotherapy, radiotherapy and/or chemoradiotherapy [1-6]. Furthermore, treatment with any of the above options for lung tumors that are already cavitated at the time of diagnosis has been associated with an increased risk of complications, with severe hemoptysis and infection being the most feared [7-10].

In most cases, the tumor cavity is located in the lung parenchyma, and its characteristics can be studied only in imaging studies [11-13]. To our knowledge, endoscopically visible, central airway necrosis has been rarely described and exclusively after radiotherapy or chemoradiotherapy [14-16].

The aim of the present manuscript is to provide the first description of the clinical, imaging, pathological, and molecular characteristics of an exceedingly rare series of patients exhibiting a centrally located, endoscopically visible cancer cavity.

Case Series

Table 1 summarizes the main demographic, clinical, histological, and molecular characteristics of the five patients described below in greater detail.

Case Report #1

A 77-year-old woman, a never-smoker, presented with a 2-month history of hemoptysis and massive weight loss (13 kg). Her Eastern Cooperative Oncology Group (ECOG) performance status was 3. A whole-body computed tomography (CT) scan showed a 50×48 mm cavitated lung mass of the left lower lobe (Figure 1A) and two brain metastases. At bronchoscopy, a single large cavity originating at the level of the lower lobe bronchus orifice and ending up in the lung parenchyma, with complete loss of the regional bronchial anatomy, was evident (Figure 1B; Video 1). Histological examination of the bronchial biopsies revealed a TTF1+ pulmonary adenocarcinoma. The culture of bronchial washing performed within the cavity grew *Enterococcus faecium* and *Aspergillus fumigatus* in the absence of any clinical or laboratory sign of infection. The tumor molecular profiling showed a PD-L1 tumor proportion score (TPS) of 55%, whereas *EGFR*, *ALK*, *ROS1*, and *BRAF* were negative. The patient did not receive any specific oncologic treatment due to her poor performance status and died 22 days after the diagnosis.

Case Report #2

A 74-year-old man, current smoker, presented with cough and hemoptysis of 2 weeks duration. His ECOG performance status was 2. A CT scan of the chest showed a 28×24 mm cavitated lesion of the right upper lobe (Figure 1C), whereas a positron emission tomography (PET) demonstrated a marked uptake of the lung lesion and of both the adrenal glands. Bronchoscopy revealed a large cavity originating from the origin of the right upper lobe bronchus, with complete loss of the regional bronchial anatomy (Figure 1D; Video 2). Histopathologic analysis of the bronchial biopsies revealed a TTF1+ lung adenocarcinoma with wild-type gene status

and a PD-L1 TPS of <1%. *Staphylococcus Aureus* and *Branhamella Catarrhalis* were cultured from the bronchial washing in the absence of clinical or laboratory signs of infection. After a 10-day course of antibiotic treatment with amoxicillin/clavulanic acid, chemo-immunotherapy combination (carboplatin AUC4, pemetrexed 375 mg/mq, pembrolizumab 200 mg q21) was initiated in August 2020. The treatment allowed for the achievement of disease stability until March 2021 when a pulmonary progression was observed. At this point, second-line treatment with docetaxel g1q21 was started and six cycles were completed. The treatment was well tolerated, and the disease remained stable until October 2021 when a thoracic progression (lung, pleura) was noted. In November 2021, a third-line treatment with gemcitabine g1.8 q21 was started and is still ongoing. The patient is alive and relatively well (ECOG performance status 2) 580 days after the initial diagnosis.

Case Report #3

An 85-year-old, a never-smoking female patient, was referred to the interventional pulmonology outpatient clinic complaining of cough, hemoptysis, and weight loss (6 kg in 12 months). Her ECOG performance status was 3. A CT scan performed on hospital admission showed a 61×47 mm, massively cavitated lesion of the left upper lobe and an ipsilateral pleural effusion. Bronchoscopy showed a large, endoscopically visible cavity that could be explored from the apical segment of the left upper lobe bronchus and ended up directly in the lung parenchyma. Biopsies from the lesion allowed us to diagnose squamous cell carcinoma, which had a PD-L1 TPS of 30-40%. No pathogens were cultured from the bronchial washing. The patient was considered unfit for any oncologic treatment due to her age and poor performance status and died 132 days after the diagnosis.

Case Report #4

A 50-year-old man, a former smoker, presented to the emergency room with a history of weight loss (7 kg in the previous 4 months), cough, and recent hemoptysis. His ECOG performance status was 2. A contrast-enhanced CT scan showed a large cavitated mass (87×68 mm) of the right upper lobe associated with ipsilateral

Table 1. Demographic, clinical, histological and molecular characteristics of the five patients.

#	Sex/Age	Smoking	Timing of diagnosis*	Symptoms	Histology	Cultures	TNM v.8 (stage)	Genotyping	PD-L1 (TPS)	Treatment (line)	Survival [#]
#1	F / 77	Never	Onset	Hemoptysis Weight loss	Adeno	<i>E. faecium</i> <i>A. fumigatus</i>	T4N0M1c (IV)	Wild type	55%	None	22
#2	M / 74	Current	Onset	Hemoptysis	Adeno	<i>S. Aureus</i> <i>B. Catarrhalis</i>	T3N2M1c (IV)	Wild type	<1%	CDBCA-Pem-Pembro (I); CDDP-Doc (II); Gem (III)	580 ^o
#3	F / 85	Never	Onset	Hemoptysis Weight loss	SqCC	No growth	T4N0M1a (IV)	Not indicated	40%	None	132
#4	M / 50	Former	Onset	Hemoptysis Weight loss	Adeno	No growth	T4N2M1c (IV)	KRAS p.G13D	<1%	CDDP-Pem	156
#5	M / 57	Former	After IO-RT	Fever Hypoxemia	SqCC	<i>S. maltophilia</i> <i>C. albicans</i>	T4N2M1a (IV)	Not indicated	70%	Pem-RT	38

*Referred to diagnosis of the central airway disruption; #days after the diagnosis of the airway disruption; ^opatient still alive; TNM, tumor nodes metastasis classification 8th edition; TPS, tumor proportion score; F, female; M, male; Adeno, adenocarcinoma; SqCC, squamous-cell carcinoma; CDBCA, carboplatin; Pem, pemetrexed; Pembro, pembrolizumab; Doc, docetaxel; Gem, gemcitabine; CDDP, cisplatin; IO, immunotherapy; RT, radiotherapy.

massive mediastinal lymph node involvement. A PET scan demonstrated a marked uptake of the pulmonary lesion, the mediastinal lymph nodes, and the left adrenal gland. Bronchoscopy revealed a large cavity that originated at the level of the right upper lobe bronchus outlet, was almost completely occupied by fibrin, and disrupted the normal bronchial anatomy, ending up directly in the lung parenchyma. Histopathologic and molecular analysis of bronchial biopsies revealed a TTF1+ lung adenocarcinoma with a *KRAS* mutation (p.G13D) and a PD-L1 expression of <1%. No pathogens were isolated from the bronchial washing. The patient underwent treatment with pemetrexed/cisplatin doublet chemotherapy (4 cycles), but neither clinical nor radiological significant response were obtained, and he died 156 days after the diagnosis.

Case Report #5

A 57-year-old male, a former smoker, underwent a diagnostic work-up for a dry cough which had worsened progressively over 5 months. Contrast-enhanced CT of the chest showed a right upper lobe solid mass which was surrounded by lymphangitic carcinomatosis, infiltrated the right upper lobe bronchus, the mediastinal fat, and, partially, the superior vena cava. Furthermore, markedly enlarged lymph nodes were evident in stations #4R, #7, #8R, #10R, and #11Rs. Histologic examination of bronchial biopsies taken from the right upper lobe and of endobronchial ultrasound-guided transbronchial needle aspiration samples obtained from lymph node #4R

revealed a squamous cell carcinoma with a PD-L1 TPS of 70%. A first-line treatment with pembrolizumab (200 mg q 21) was initiated but after the 3rd cycle, the patient showed frank signs of the mediastinal syndrome and a CT revealed a local progression of the tumor, which almost completely obstructed the superior vena cava, as well as signs of interstitial lung disease. At this point, steps were taken to perform palliative radiotherapy, which led to a rapid regression of the signs of mediastinal syndrome. However, 1 month after radiotherapy and shortly after the 4th pembrolizumab administration, the patient was admitted to the hospital for fever not responsive to ciprofloxacin treatment and progressive respiratory failure. A new CT of the chest showed a marked worsening of the interstitial changes and massive cavitation (89×60 mm) of the right upper lobe mass (Figure 1E). At bronchoscopy (Video 3), the anterior and apical segments of the right upper lobe bronchus were replaced by a large cavity (Figure 1F), which led into the pleural space through a large opening located at the bottom of the cavity (Video 3). Bronchial washing performed into the lesion grew *Stenotrophomonas Maltophilia* and *Candida Albicans*. Despite antibiotic and antifungal treatment, as well as non-invasive ventilation delivered through a helmet, the patient died 38 days after the hospital admission.

Discussion

Herein, we have provided the first organic description of a series of lung cancer patients whose primary tumor caused the dis-




Figure 1. Bronchoscopically-visible central airway disruption in 3 patients of the present series. A) Computed tomography (CT) of the chest showing a large cavitated mass of the left lower lobe bronchus (arrow); B) Corresponding videobronchoscopy image from the orifice of the left lower lobe bronchus showing the large cavity. The arrows highlight a severed segmental airway (see also Video 1); C) CT of the chest showing a cavitory lesion of the right upper lobe with direct communication with the origin of the right upper lobe bronchus (arrow); D) corresponding videobronchoscopy image showing the cavity, whose walls are largely covered with fibrin/necrotic tissue. Three severed segmental airways can be seen (arrows) (see also Video 2); E) chest CT showing a large cavitory lesion of the right upper lobe (arrows), as well as extensive bilateral ground glass opacities and traction bronchiectasis/bronchiolectasis; F) corresponding videobronchoscopy image showing the inner aspect of the thoracic wall, clearly visible from a large opening located at the bottom of the cavity (see also Video 3).

ruption of the normal airway anatomy at the level of lobar or segmental bronchi, leading to the formation of an endoscopically visible cavity that ended up in the lung parenchyma or even into the pleural space.

In four of the five patients described, the central tumor cavity was already present at the time of the initial diagnosis, before any specific treatment. Although pathogenic organisms were cultured in the bronchial washing obtained from the cavity in two out of these four patients (*Enterococcus Faecium* and *Aspergillus Fumigatus* in Case Report #1; *Staphylococcus Aureus* and *Branhamella Catarrhalis* in Case Report #2), none of them had clinical or laboratory signs of infection, and we hypothesize that these organisms were simple colonizers. More likely, the pathogenesis of cavity formation in these patients was related to a check-valve mechanism secondary to bronchial obstruction and/or to ischemia secondary to vascular invasion or excessive tumor growth outpacing neoplastic vascularization. Furthermore, as most of these cases (three of four) were diagnosed between June and July 2020, we believe that the diagnostic and consequent treatment delays observed during the first wave of the COVID-19 pandemic might have contributed significantly to the occurrence of the massive lesion necrosis [17-19].

In the remaining patient, the primary tumor presented as a solid mass at the time of diagnosis and cavitated after first-line treatment. We believe that the *primum movens* towards the necrotic evolution, in this case, was the palliative radiotherapy of the tumor, and massive right paratracheal lymphadenopathy aimed at relieving a clinically evident mediastinal syndrome secondary to obstruction of the superior vena cava. However, it is likely that a secondary infection of the lesion contributed to worsening the process. In fact, the patient complained of fever and was not responsive to antibiotics in the 10 days before referral to the emergency room, and bronchial washing performed in the cavity grew *Stenotrophomonas Maltophilia* and *Candida Albicans*.

Unlike cavitated tumors of the lung parenchyma, which are more frequently of squamous histology [5], we did not find such a preferential association in our series. In addition, the clinical presentation of the four treatment-naïve patients was strikingly similar. All of them, in fact, presented with metastatic disease, poor ECOG performance status, similar clinical complaints, and a lack of actionable mutations. As for the symptoms, hemoptysis was present in all of them, and three complained also of clinically important weight loss. Among the three patients with adenocarcinoma, two had a wild-type gene status, and one had a *KRAS* p.G13D mutation.

Although the limited number of cases does not allow us to draw definitive conclusions, the prognosis associated with central cavitary tumors seems very poor. The only patient who had a meaningful response to treatment and is still alive 19 months after the initial diagnosis is the one (Case Report #2) who presented with the lowest duration of symptoms, the smallest size of the cavitated mass, and the best performance status. This emphasizes the importance of not underestimating hemoptysis, which is invariably present in these patients, to identify them early during the disease course when they are still fit enough to receive treatment.

Conclusions

In conclusion, our series suggests that endoscopically visible, central cavitary tumors can be found even at the time of initial diagnosis and tend to have similar clinical (advanced disease, poor performance status, hemoptysis) and molecular (lack of actionable mutations) characteristics, which portend a poor prognosis.

References

1. Marom EM, Martinez CH, Truong MT, et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. *J Thorac Oncol* 2008;3:351-7.
2. Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. *J Clin Oncol* 2009;27:404-10.
3. Calvetti L, Aprile G. influence and mechanisms of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat? *Transl Lung Canc Res* 2019;8:319-22.
4. Wang R, Li K, Pi J, Zhu M. Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: a case report. *Thorac Cancer* 2020;11:2727-30.
5. Zarogoulidis P, Athanasiou E, Tsiouda T, et al. Immunotherapy "shock": a case series of PDL1 100% and pembrolizumab first-line treatment. *Resp Med Case Rep* 2017;22:197-202.
6. Phernambucq E, Hartemink K, Smit E, et al. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes. *J Thorac Oncol* 2012;7:1271-5.
7. Sandler AB, Schiller JH, Gray R3, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. *J Clin Oncol* 2009;27:1405-12.
8. Tokito T, Shukuya T, Akamatsu H, et al. Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions. *Resp Invest* 2014;52:184-9.
9. Razazi K, Parrot A, Khalil A, et al. Severe haemoptysis in patients with non-small-cell lung cancer. *Eur Resp J* 2015;45:756-64.
10. Ito M, Niho S, Nihei K, Yoh K, Ohmatsu H, Ohe Y. Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. *BMC Cancer* 2012;12:27.
11. Nguyen NC, Abhisheek K, Nyon S, et al. Are there radiographic, metabolic, and prognostic differences between cavitary and non-cavitary nonsmall cell lung carcinoma? A retrospective fluorodeoxyglucose positron emission tomography/computed tomography study. *Ann Thorac Med* 2016;11:49-54.
12. Pentheroudakis G, Kostadima L, Fountzilas G, et al. Cavitating squamous cell lung carcinoma – distinct entity or not? Analysis of radiologic, histologic and clinical features. *Lung Cancer* 2004;45:349-55.
13. Liu Z, Feng H, Zhang Z, et al. Clinicopathological characteristics of solitary cavitary lung cancer: a case-control study. *J Thorac Dis* 2020;12:3148-56.
14. Corradetti MN, Haas AR, Rengan RR. Central airway necrosis after stereotactic body-radiation therapy. *N Engl J Med* 2012;366:2327-9.
15. Alraiyes AH, Alraiyes MC, Abbas A. Radiation-associated airway necrosis. *Ochsner J* 2013;13:273-5.
16. Kim IA, Koh HK, Kim SJ, et al. Malignant tracheal necrosis and

- fistula formation following palliative chemoradiotherapy: a case report. *J Thorac Dis* 2017;9:E402-7.
17. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol* 2020;21:1023-34.
 18. Leong TL. Delayed access to lung cancer screening and treatment during the COVID-19 pandemic: are we headed for a lung cancer pandemic? *Respirology* 2021;26:145-6.
 19. Trisolini R, Magnini D, Livi V, et al. Pattern of cancer patient referral and organizational model of an interventional pulmonology programme during the Covid-19 pandemic. *ERJ Open Res* 2021;7:00152-2021.

Non-commercial use only

Online supplementary material:

Video 1. Left lower lobe central cavity.

Video 2. Right upper lobe central cavity.

Video 3. Right upper lobe central cavity.